J&J’s iBOT Wins Expedited FDA Approval, Faces Reimbursement Roadblocks
This article was originally published in The Gray Sheet
Executive Summary
FDA will evaluate the need for labeling revisions to Johnson & Johnson/Independence Technology's iBOT 3000 stair-climbing wheelchair upon receipt of four semi-annual reports from the company